Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2

Terminated

Conditions: Precursor-B Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma
Lymphoma
Leukemia

Interventions: Drug: Cytarabine
Drug: Daunorubicin
Drug: Vincristine
Drug: Prednisone
Drug: PEG asparaginase
Drug: Ofatumumab
Drug: Rituximab
Drug: Methotrexate
Drug: Cyclophosphamide
Drug: Mercaptopurine
Drug: Doxorubicin
Drug: Dexamethasone acetate
Drug: Thioguanine

First Posted Date: 2015-04-17

Last Posted Date: 2018-06-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT02419469

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin

Phase 2

Completed

Conditions: Classical Hodgkin Lymphoma

Interventions: Drug: Bendamustine
Drug: Prednisone
Drug: Vinblastine
Drug: Doxorubicin

First Posted Date: 2015-04-10

Last Posted Date: 2021-02-21

Lead Sponsor: The Lymphoma Academic Research Organisation

Target Recruit Count: 90

Registration Number: NCT02414568

Locations: 🇫🇷
CHR de Metz-Thionville - Hôpital de Mercy, Metz, France
🇫🇷
Hôpital de la Pitié-Salpêtrière, Paris, France
🇫🇷
CHRU de Nîmes, Nîmes, France

and more 37 locations

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Phase 3

Completed

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Fludarabine

First Posted Date: 2015-04-02

Last Posted Date: 2024-11-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 139

Registration Number: NCT02406092

Locations: 🇲🇦
Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique, Rabat, Morocco
🇩🇿
Hôpital Dorban CHU Annaba, Service d'Hématologie, Annaba, Algeria
🇩🇿
Centre hospitalo-univerisitaire de Tizi Ouzou - Nedir Mohamed;Service d'hématologie, Tizi Ouzou, Algeria

and more 10 locations

Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD

Not Applicable

Recruiting

Conditions: Pulmonary Disease, Chronic Obstructive
Adverse Effect of Glucocorticoids and Synthetic Analogues
Disease Exacerbation

Interventions: Drug: Placebo
Drug: Prednisone

First Posted Date: 2015-03-12

Last Posted Date: 2023-09-06

Lead Sponsor: Prof. Dr. Jörg Leuppi

Target Recruit Count: 470

Registration Number: NCT02386735

Locations: 🇨🇭
Kantonsspital Baselland, Liestal, BL, Switzerland

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

Phase 1

Withdrawn

Conditions: Cancer

Interventions: Drug: Afuresertib
Drug: Enzalutamide
Drug: Abiraterone
Drug: Prednisone

First Posted Date: 2015-03-05

Last Posted Date: 2016-10-06

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02380313

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

Phase 2

Terminated

Conditions: Prostate Cancer Metastatic

Interventions: Drug: Ezalutamide
Drug: Cabazitaxel XRP6258
Drug: Prednisone
Drug: Abiraterone acetate

First Posted Date: 2015-03-04

Last Posted Date: 2019-06-21

Lead Sponsor: Sanofi

Target Recruit Count: 8

Registration Number: NCT02379390

Locations: 🇨🇦
Investigational Site Number 124005, Hamilton, Canada
🇨🇦
Investigational Site Number 124002, Montreal, Canada
🇨🇦
Investigational Site Number 124009, Quebec, Canada

and more 21 locations

Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome

Phase 4

Conditions: Sjogren's Syndrome

Interventions: Drug: Cyclosporin A
Drug: Placebo
Drug: Prednisone
Drug: Calcium carbonate D

First Posted Date: 2015-02-25

Last Posted Date: 2020-05-22

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 240

Registration Number: NCT02370550

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Prednisone in Chronic Rhinosinusitis Without Nasal Polyps

Phase 3

Conditions: Sinusitis
Chronic Rhinosinusitis

Interventions: Drug: Placebo
Drug: Prednisone

First Posted Date: 2015-02-20

Last Posted Date: 2015-06-04

Lead Sponsor: University of Chile

Target Recruit Count: 90

Registration Number: NCT02367118

Locations: 🇨🇱
Hospital del Salvador, Santiago, Region Metropolitana, Chile

Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage

Phase 3

Terminated

Conditions: Lymphoma, Extranodal NK-T-Cell

Interventions: Drug: Gemcitabine
Drug: Etoposide
Drug: Oxaliplatin
Drug: Vincristine
Drug: Pegaspargase
Drug: Doxorubicin
Radiation: IMRT
Drug: Cyclophosphamide
Drug: Prednisone

First Posted Date: 2015-02-09

Last Posted Date: 2018-05-09

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 50

Registration Number: NCT02359162

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Primary Mediastinal B-cell Lymphoma (PMBCL)
Transformed Follicular Lymphoma (TFL)
High Grade B-cell Lymphoma (HGBCL)
Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Relapsed Diffuse Large B-Cell Lymphoma

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Levetiracetam
Drug: Tocilizumab
Drug: Dexamethasone
Drug: Doxorubicin
Drug: High-dose methylprednisolone
Drug: Prednisone
Drug: Bendamustine
Drug: Vincristine
Drug: Rituximab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Methylprednisolone
Drug: Etoposide
Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Cisplatin

First Posted Date: 2015-01-28

Last Posted Date: 2024-06-04

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 307

Registration Number: NCT02348216

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
University of California Los Angeles (UCLA), Santa Monica, California, United States
🇨🇦
Princess Margaret, Toronto, Ontario, Canada

and more 33 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy